Literature DB >> 7487614

Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group.

.   

Abstract

OBJECTIVE: To determine the roles of immediate pars plana vitrectomy (VIT) and systemic antibiotic treatment in the management of postoperative endophthalmitis.
DESIGN: Investigator-initiated, multicenter, randomized clinical trial.
SETTING: Private and university-based retina-vitreous practices. PATIENTS: A total of 420 patients who had clinical evidence of endophthalmitis within 6 weeks after cataract surgery or secondary intraocular lens implantation.
INTERVENTIONS: Random assignment according to a 2 x 2 factorial design to treatment with VIT or vitreous tap or biopsy (TAP) and to treatment with or without systemic antibiotics (ceftazidime and amikacin). MAIN OUTCOME MEASURES: A 9-month evaluation of visual acuity assessed by an Early Treatment Diabetic Retinopathy Study acuity chart and media clarity assessed both clinically and photographically.
RESULTS: There was no difference in final visual acuity or media clarity with or without the use of systemic antibiotics. In patients whose initial visual acuity was hand motions or better, there was no difference in visual outcome whether or not an immediate VIT was performed. However, in the subgroup of patients with initial light perception-only vision, VIT produced a threefold increase in the frequency of achieving 20/40 or better acuity (33% vs 11%), approximately a twofold chance of achieving 20/100 or better acuity (56% vs 30%), and a 50% decrease in the frequency of severe visual loss (20% vs 47%) over TAP. In this group of patients, the difference between VIT and TAP was statistically significant (P < .001, log rank test for cumulative visual acuity scores) over the entire range of vision.
CONCLUSIONS: Omission of systemic antibiotic treatment can reduce toxic effects, costs, and length of hospital stay. Routine immediate VIT is not necessary in patients with better than light perception vision at presentation but is of substantial benefit for those who have light perception-only vision.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7487614

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  305 in total

1.  Macular infarction after intravitreal amikacin: mounting evidence against amikacin.

Authors:  G Galloway; A Ramsay; K Jordan; A Vivian
Journal:  Br J Ophthalmol       Date:  2002-03       Impact factor: 4.638

2.  The dangers of sublethal carvacrol exposure: increases in virulence of Bacillus cereus during endophthalmitis.

Authors:  Niloofar Rajabli; Lauren Williamson; Pierre S Nimmer; Marie Kelly-Worden; Jill S Bange; Yenling Ho; John L McKillip
Journal:  Int J Biochem Mol Biol       Date:  2018-10-08

Review 3.  The microbiology of endophthalmitis: global trends and a local perspective.

Authors:  Y Keynan; Y Finkelman; P Lagacé-Wiens
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-05       Impact factor: 3.267

4.  Biocompatibility of pooled human immunoglobulin (Gamunex 10%™) with ocular infusion solutions (BSS™ and BSS Plus™): an in vitro evaluation of a potential antitoxin treatment for infectious endophthalmitis.

Authors:  Dennis P Han; William J O'Brien; Brian Higgins
Journal:  J Ocul Pharmacol Ther       Date:  2011-06-01       Impact factor: 2.671

5.  Infectious Endophthalmitis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

6.  Gemella haemolysans acute postoperative endophthalmitis.

Authors:  S V Raman; N Evans; T J Freegard; R Cunningham
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

Review 7.  Endophthalmitis: Then and Now.

Authors:  Nidhi Relhan; Richard K Forster; Harry W Flynn
Journal:  Am J Ophthalmol       Date:  2017-12-05       Impact factor: 5.258

8.  Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis.

Authors:  Dennis P Han
Journal:  Trans Am Ophthalmol Soc       Date:  2004

9.  Culture-Proven Endophthalmitis After Intravitreal Injection: A 10-Year Analysis.

Authors:  Joseph M Simonett; Austin Igelman; Stanford C Taylor; J Peter Campbell; Thomas S Hwang; Phoebe Lin; Andreas K Lauer; Christina J Flaxel
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2019-01-01       Impact factor: 1.300

10.  Burkholderia cepacia endophthalmitis, in a penicillin allergic patient, following a ranibizumab injection.

Authors:  Norman Saffra; Emily Moriarty
Journal:  BMJ Case Rep       Date:  2014-02-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.